Document Detail


The role of tocilizumab in the management of rheumatoid arthritis.
MedLine Citation:
PMID:  22849354     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: The introduction of biological treatments has improved the outlook for patients diagnosed with rheumatoid arthritis. There are now a range of different agents, targeting various pathways involved in the inflammatory process. Tocilizumab , a fully humanised anti-interleukin-6 receptor monoclonal antibody is licensed for the treatment of rheumatoid arthritis and systemic juvenile idiopathic arthritis.
AREAS COVERED: This article reviews and appraises the available evidence regarding the efficacy and safety of tocilizumab in rheumatoid arthritis, as identified in PubMed and Embase searches.
EXPERT OPINION: Clinical trial data suggest that tocilizumab has similar efficacy both clinically and in reducing structural progression to that seen with the TNF inhibitors. Patients who might be particularly suitable for tocilizumab are those who have failed multiple TNF inhibitors, those with a high inflammatory response as part of their disease and those unable to tolerate methotrexate, given the good responses seen with monotherapy.
Authors:
Zoe Ash; Paul Emery
Related Documents :
10932284 - Plasma homocysteine and mthfr c677t genotype in levodopa-treated patients with pd.
10410784 - The case for neural tissue transplantation as a treatment for parkinson's disease.
15852454 - Dementia in parkinson's disease: a post-mortem study in a population of brain donors.
11008194 - Double blinded evaluation of the effects of pallidal and subthalamic nucleus stimulatio...
9538674 - Stiff-man syndrome. results of interviews and psychologic testing.
3971754 - Radionuclide angiography in the quantitation of mitral regurgitation.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2012-07-31
Journal Detail:
Title:  Expert opinion on biological therapy     Volume:  12     ISSN:  1744-7682     ISO Abbreviation:  Expert Opin Biol Ther     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-08-14     Completed Date:  2013-01-08     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  101125414     Medline TA:  Expert Opin Biol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  1277-89     Citation Subset:  IM    
Affiliation:
University of Leeds, Leeds Institute of Molecular Medicine, Leeds Teaching Hospitals, Section of Musculoskeletal Disease, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antibodies, Monoclonal, Humanized / therapeutic use*
Antirheumatic Agents / therapeutic use*
Arthritis, Rheumatoid / drug therapy*,  immunology
Disease Progression
Humans
Interleukin-6 / metabolism
Patient Selection
Receptors, Interleukin-6 / antagonists & inhibitors,  metabolism
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal, Humanized; 0/Antirheumatic Agents; 0/IL6 protein, human; 0/IL6R protein, human; 0/Interleukin-6; 0/Receptors, Interleukin-6; 0/tocilizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Fermentation responses and in vitro radical scavenging activities of Fagopyrum esculentum.
Next Document:  Environmental species sorting dominates forest-bird community assembly across scales.